Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Marina Noris, Miriam Galbusera, Sara Gastoldi, Paolo Macor, Federica Banterla, Elena Bresin, Claudio Tripodo, Serena Bettoni, Roberta Donadelli, Elisabetta Valoti, Francesco Tedesco, Alessandro Amore, Rosanna Coppo, Piero Ruggenenti, Eliana Gotti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endothelial cells (HMEC-1). In adenosine 5'-diphosphate-activated HMEC-1, also sera from 84% and 100% of patients in remission, and from all unaffected mutation carriers, induced excessive C3 and C5b-9 deposits. At variance, in most patients with C3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced endothelial C5b-9 deposits were normal. In 8 eculizumab-treated aHUS patients, C3/SC5b-9 circulating levels did not change posteculizumab, whereas serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or even preceded remission, and guided drug dosing and timing. These results point to efficient complement inhibition on endothelium for aHUS treatment. C5b-9 endothelial deposits might help monitor eculizumab effectiveness, avoid drug overexposure, and save money considering the extremely high cost of the drug.

Original languageEnglish
Pages (from-to)1715-1726
Number of pages12
JournalBlood
Volume124
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Complement Membrane Attack Complex
Complement Activation
Deposits
Chemical activation
Serum
Pharmaceutical Preparations
Complement Factor H
Therapeutics
Complement C2
Diphosphates
Membranoproliferative Glomerulonephritis
Endothelial cells
Mutation
Antigen-Antibody Complex
Drug Costs
Titration
Adenosine
Assays
Adenosine Diphosphate
Endothelium

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. / Noris, Marina; Galbusera, Miriam; Gastoldi, Sara; Macor, Paolo; Banterla, Federica; Bresin, Elena; Tripodo, Claudio; Bettoni, Serena; Donadelli, Roberta; Valoti, Elisabetta; Tedesco, Francesco; Amore, Alessandro; Coppo, Rosanna; Ruggenenti, Piero; Gotti, Eliana; Remuzzi, Giuseppe.

In: Blood, Vol. 124, No. 11, 2014, p. 1715-1726.

Research output: Contribution to journalArticle

Noris, M, Galbusera, M, Gastoldi, S, Macor, P, Banterla, F, Bresin, E, Tripodo, C, Bettoni, S, Donadelli, R, Valoti, E, Tedesco, F, Amore, A, Coppo, R, Ruggenenti, P, Gotti, E & Remuzzi, G 2014, 'Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.', Blood, vol. 124, no. 11, pp. 1715-1726. https://doi.org/10.1182/blood-2014-02-558296
Noris, Marina ; Galbusera, Miriam ; Gastoldi, Sara ; Macor, Paolo ; Banterla, Federica ; Bresin, Elena ; Tripodo, Claudio ; Bettoni, Serena ; Donadelli, Roberta ; Valoti, Elisabetta ; Tedesco, Francesco ; Amore, Alessandro ; Coppo, Rosanna ; Ruggenenti, Piero ; Gotti, Eliana ; Remuzzi, Giuseppe. / Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. In: Blood. 2014 ; Vol. 124, No. 11. pp. 1715-1726.
@article{afc314c91be24562af75960f281b6d6c,
title = "Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.",
abstract = "Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47{\%} to 64{\%} of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endothelial cells (HMEC-1). In adenosine 5'-diphosphate-activated HMEC-1, also sera from 84{\%} and 100{\%} of patients in remission, and from all unaffected mutation carriers, induced excessive C3 and C5b-9 deposits. At variance, in most patients with C3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced endothelial C5b-9 deposits were normal. In 8 eculizumab-treated aHUS patients, C3/SC5b-9 circulating levels did not change posteculizumab, whereas serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or even preceded remission, and guided drug dosing and timing. These results point to efficient complement inhibition on endothelium for aHUS treatment. C5b-9 endothelial deposits might help monitor eculizumab effectiveness, avoid drug overexposure, and save money considering the extremely high cost of the drug.",
author = "Marina Noris and Miriam Galbusera and Sara Gastoldi and Paolo Macor and Federica Banterla and Elena Bresin and Claudio Tripodo and Serena Bettoni and Roberta Donadelli and Elisabetta Valoti and Francesco Tedesco and Alessandro Amore and Rosanna Coppo and Piero Ruggenenti and Eliana Gotti and Giuseppe Remuzzi",
year = "2014",
doi = "10.1182/blood-2014-02-558296",
language = "English",
volume = "124",
pages = "1715--1726",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

AU - Noris, Marina

AU - Galbusera, Miriam

AU - Gastoldi, Sara

AU - Macor, Paolo

AU - Banterla, Federica

AU - Bresin, Elena

AU - Tripodo, Claudio

AU - Bettoni, Serena

AU - Donadelli, Roberta

AU - Valoti, Elisabetta

AU - Tedesco, Francesco

AU - Amore, Alessandro

AU - Coppo, Rosanna

AU - Ruggenenti, Piero

AU - Gotti, Eliana

AU - Remuzzi, Giuseppe

PY - 2014

Y1 - 2014

N2 - Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endothelial cells (HMEC-1). In adenosine 5'-diphosphate-activated HMEC-1, also sera from 84% and 100% of patients in remission, and from all unaffected mutation carriers, induced excessive C3 and C5b-9 deposits. At variance, in most patients with C3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced endothelial C5b-9 deposits were normal. In 8 eculizumab-treated aHUS patients, C3/SC5b-9 circulating levels did not change posteculizumab, whereas serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or even preceded remission, and guided drug dosing and timing. These results point to efficient complement inhibition on endothelium for aHUS treatment. C5b-9 endothelial deposits might help monitor eculizumab effectiveness, avoid drug overexposure, and save money considering the extremely high cost of the drug.

AB - Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endothelial cells (HMEC-1). In adenosine 5'-diphosphate-activated HMEC-1, also sera from 84% and 100% of patients in remission, and from all unaffected mutation carriers, induced excessive C3 and C5b-9 deposits. At variance, in most patients with C3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced endothelial C5b-9 deposits were normal. In 8 eculizumab-treated aHUS patients, C3/SC5b-9 circulating levels did not change posteculizumab, whereas serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or even preceded remission, and guided drug dosing and timing. These results point to efficient complement inhibition on endothelium for aHUS treatment. C5b-9 endothelial deposits might help monitor eculizumab effectiveness, avoid drug overexposure, and save money considering the extremely high cost of the drug.

UR - http://www.scopus.com/inward/record.url?scp=84908611206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908611206&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-02-558296

DO - 10.1182/blood-2014-02-558296

M3 - Article

VL - 124

SP - 1715

EP - 1726

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -